Articles published by Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
February 07, 2023
Via Business Wire
Tickers
AMLX

Amylyx Pharmaceuticals Announces Completion of Enrollment in Global Phase 3 PHOENIX Trial of AMX0035 in ALS
February 02, 2023
Via Business Wire
Tickers
AMLX

Amylyx Pharmaceuticals to Participate in the Evercore ISI 5th Annual HealthCONx Conference
November 22, 2022
Via Business Wire
Tickers
AMLX

Amylyx Pharmaceuticals Reports Third Quarter 2022 Financial Results
November 10, 2022
Via Business Wire
Tickers
AMLX

Amylyx Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 10, 2022
November 03, 2022
Via Business Wire
Tickers
AMLX


Amylyx Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
October 06, 2022
Via Business Wire
Tickers
AMLX

Amylyx Pharmaceuticals Announces Launch of Public Offering
October 04, 2022
Via Business Wire
Tickers
AMLX

Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for the Treatment of ALS
September 29, 2022
Via Business Wire
Tickers
AMLX


Amylyx Pharmaceuticals Announces FDA Advisory Committee Supports Approval of AMX0035 for the Treatment of ALS
September 07, 2022
Via Business Wire
Tickers
AMLX



Via Business Wire
Tickers
AMLX









Via Business Wire
Tickers
AMLX



Via Business Wire
Tickers
AMLX




Via Business Wire
Tickers
AMLX
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.